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study because of worsening of psychosis. Functional activity was measured using
the resource utilization inventory. Non-adherent patients are those with non-ad-
herence as reason for discontinuation of the antipsychotic medication used at
baseline, per physician rating. RESULTS: Over the 2-year study, 30% of patients
have relapsed and 8% were hospitalized, without significant differences between
the two medication formulations. Patients non-adherent before baseline were
more likely to be hospitalized (14%) compared to adherent patients (7% hospital-
ized, p0.05). Relapse in non-adherent patients was 36% compared to 29% in ad-
herent patients. A logistic regression model on baseline factors associated with
relapse found that a greater extent of functional activity was associated with a
lower risk of relapse. The risk of subsequent hospitalization was significantly as-
sociated only with previous hospitalization. CONCLUSIONS: In this 2-year open
label study, the rate of relapse and hospitalization was similarly low among pa-
tients treated with oral olanzapine or olanzapine-LAI. While prior non-adherence
with oral antipsychotics and previous hospitalization were associated with hospi-
talization, only the latter predicted subsequent hospitalization in the logistic
model. Lower risk of relapse was associated with a greater level of productivity.
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OBJECTIVES: Treatment optimization for patients with schizophrenia remains a
challenge, and it is often difficult to determine whether augmenting the current
medication or switching to another will better benefit a patient. This post hoc
analysis compares outcome measures between patients whose antipsychotic med-
ication was either augmented or switched. METHODS: Adult outpatients receiving
oral antipsychotic treatment for schizophrenia were assessed during a 12-month,
multi-country, observational study (F1D-AY-B033). Clinical and functional out-
comes were assessed at the time of first treatment switch/augmentation (0–14
days preceding change) and compared between patients undergoing medication
augmentation or switching. Due to low numbers of patients with such data, inter-
pretation of findings is based on effect size (ES). RESULTS: Data at the time of
medication change were available for 87 patients (34 augmented, 53 switched). The
primary reason for treatment change in both groups was inadequate response, but
lack of adherence was more prevalent in the switched group (26.4% versus 8.8%).
Although changes in clinical severity from study initiation to medication change
were similar (per the Clinical Global Impressions—Severity scale), patients’ phys-
ical well being, as measured by physical component scores of the 12-item Short
Form Health Survey (SF-12), improved in the augmented group but worsened in the
switched group (augmented: 7.7111.98, switched: –1.8710.98, ES0.85). Simi-
larly, mental health state improved in the augmented group but declined in the
switched group, as indicated by SF-12 mental health component scores (augment-
ed: 2.4113.64, switched: –1.089.98, ES0.314). CONCLUSIONS: Patient’s wors-
ening or lack of meaningful improvement may prompt clinicians to switch anti-
psychotic medications, whereas, when a patient shows improvement, clinicians
appear more likely to try to bolster the improvement through augmentation with
another antipsychotic medication. Current findings are consistent with physicians’
stated reasons for augmenting versus switching antipsychotics in the treatment of
schizophrenia. Confirmation of these findings requires further research.
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OBJECTIVES: The risk of bradycardia and its consequences from use of cholinest-
erase inhibitors (ChI) in dementia was reported in epidemiological studies in 2009
and from a case series for memantine in 2008. We compared the detection and
timing of these associations between disproportionality analysis and published
epidemiological studies. METHODS: We conducted 1) a systematic review of the
literature to identify epidemiological studies reporting AEs in patients taking cur-
rently prescribed ChI and memantine, and 2) an analysis in the FDA spontaneous
Adverse Event Reporting System database (AERS) using the Empirical Bayesian
Geometric Mean (EBGM) statistic and 90% credibility intervals (90%CI), to allow for
low frequencies of drug-event pairs. A composite event consisted of any of the
following: bradycardia, bradyarrythmia, pacemaker insertion, complete atrio-ven-
tricular block and hip and femoral fracture. AEs from all drugs in AERS was the
comparator. RESULTS: A total of 246 cases suspected of being associated with ChI
and the composite event were identified. A statistically strong signal of dispropor-
tionate reporting, adjusted for age, sex and year was observed (EBGM of 6.58, 90%CI:
5.79 – 7.47). Cumulative yearly analyses revealed that the signal became statisti-
cally strong in 1997, one year after approval of the first currently used ChI. The first
signal was reported in an epidemiological study in 2009. For memantine, 69 sus-
pected cases were identified with the composite event. A statistically strong signal
of disproportionate reporting, adjusted for age, sex and year, was observed (EBGM
of 1.87; 90%CI: 1.47 – 2-38). Cumulative yearly analyses revealed that the signal
became statistically strong and stable two years after the first reported composite
event. No epidemiological studies have yet been published. CONCLUSIONS: Anal-
ysis of suspected events can be followed over time and may detect, confirm or
refute drug-event signals much earlier than epidemiological studies and inform
health technology assessments.
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OBJECTIVES: The impact on mortality is a major driver in determining the cost-
effectiveness of diagnostics and treatment of dementia disorders. We examined
the relationship between the degree of dementia severity and mortality in a longi-
tudinal, population-based study in Sweden.METHODS: From a total sample of 1810
subjects aged 75 years or older, 211 were identified as having a clinical diagnosis of
dementia at baseline and were included in the study. Disease severity was assessed
with the Mini-Mental State Examination (MMSE) as well as the Clinical Dementia
Rating (CDR), administered at baseline and again at two follow-up visits after ap-
proximately 40 and 80 months respectively. Mortality data was obtained from the
national death statistics, 10 years post baseline. Survival analysis was conducted
using Weibull regression with baseline as well as time-varying covariates. Age and
gender were also included as covariates in addition to dementia severity. RESULTS:
A total of 198 deaths were observed during the observation period, and the time to
death was 935 days on median. Annual mortality rates in females were estimated
to 12% for mild dementia (MMSE 21-26), 15% for moderate dementia (MMSE 10-20)
and 19% for severe dementia (MMSE 0-9) at baseline. The corresponding estimates
for males were 19%, 24% and 31% respectively. Each point lower result on the MMSE
scale was associated with a decrease in survival by 2.5%. There was no statistically
significant relationship between baseline CDR scores and mortality, though a trend
was seen towards increasing mortality in more severe CDR states. Similar results
were observed in an analysis incorporating changes in disease severity over time.
CONCLUSIONS: Mortality in subjects with dementia increase with the severity of
dementia, as measured by the MMSE. Incorporating differential survival by disease
severity has important implications for the long-term cost-effectiveness of diag-
nosis and therapies for dementia disorders.
Mental Health – Cost Studies
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OBJECTIVES: Prior to the approval of buprenorphine/naloxone (B/N) (Suboxone®)
we evaluated its economic impact in the treatment of heroin dependence. Three
years since its approval we aimed to reassess the economic impact of B/N consid-
ering the availability of data on its actual use in clinical practice and the changing
costs of medicines in the current economic crisis. A pharmacoeconomic modeling
was applied to evaluate the economic impact of B/N as a maintenance therapy for
opioid dependent individuals in the Spanish National Health Care System (NHS)
during a three-year period. METHODS: We used an interactive budgetary impact
analysis model that was developed to calculate the annual costs (drugs and asso-
ciated costs) to the Spanish NHS of methadone versus B/N depending on the num-
ber of patients receiving either medication. Data for the model were obtained from
scientific databases and expert panel opinion. RESULTS: It was estimated that
81.706 patients would be in agonist opioid maintenance treatment program each of
the three-years of the study. More importantly, the introduction of B/N combina-
tion has not resulted in an increase in the number of patients receiving treatment
for their opioid dependence. The budgetary impact (drugs and associated costs) for
opioid maintenance treatment in the first year of the study is expected to be 90,92
million €. In the first year of the pharmacoeconomic modeling the budgetary im-
pact of B/N would rise to 4.85 million € (4.9% of the total impact) to the NHS, with an
incremental cost of 0.86 million € (1.0% of the total impact). The mean cost per
patient in the first year with and without B/N has been calculated at € 1102 and
1113, respectively. CONCLUSIONS: With an additional cost of only € 11 per patient,
B/N is an efficient addition to the available pharmacotherapies for opioid depen-
dent patients, particularly when considering the favorable clinical aspects of this
novel medication.
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OBJECTIVES: To estimate the economic consequences of replacing the normal
tablets of quetiapine with Seroquel XR® in the treatment of schizophrenia in
Poland.METHODS: Based on the established model of the economic consequences
of schizophrenia treatment, we calculated the cost of treating schizophrenia with
quetiapine in Poland. Expenditures for the purchase of medicines, hospital costs
and the costs of lost productivity were highlighted. The analysis was performed
from a societal perspective, taking into account the Payer’s perspective, in one-year
time horizon. RESULTS: The use of Seroquel XR® will increase the population of
patients who comply with the recommended treatment, which will reduce the
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